Clinuvel (ASX:CUV) share price pinches down after Israeli breakthrough // The Motley Fool Australia

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price closed 1.15% lower today at $21.54. The dip came after the company announced that its SCENESSE product had been added to Israel’s ‘National Health Basket’ (NHB) of reimbursable services and products. 

Clinuvel Pharmaceuticals is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of genetic and vascular disorders. 

The company’s main product is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP).

What’s driving the Clinuvel share price?

Earlier today, Clinuvel announced that it had achieved a positive outcome in Israel regarding its SCENESSE treatment. The product, which is…